A Phase 1/2 Study of Vorinostat (Zolinza) in Combination With Gemtuzumab Ozogamicin (Mylotarg) and Azacitidine (Vidaza) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML).

Trial Profile

A Phase 1/2 Study of Vorinostat (Zolinza) in Combination With Gemtuzumab Ozogamicin (Mylotarg) and Azacitidine (Vidaza) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Vorinostat (Primary) ; Azacitidine; Azacitidine; Gemtuzumab ozogamicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 02 May 2013 Planned End Date changed from 1 Jun 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top